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No presente estudo foram preparadas micropartículas de poli(hidroxibutirato) contendo 
piroxicam pela técnica de emulsão-evaporação do solvente. A influência de alguns parâmetros do 
processo sobre a eficiência de encapsulação do fármaco foi avaliada por meio de um planejamento 
fatorial do tipo 23. A eficiência de encapsulação do piroxicam variou de 5,5 a 89,8%. Micropartículas 
ocas e irregulares, contendo cristais de fármaco na superfície, foram obtidas quando se utilizou 
5 mL de clorofórmio como fase interna da emulsão. Com o ensaio de liberação in vitro evidenciou-
se que, após 8 h, todo o fármaco havia sido liberado para o meio. Micropartículas esféricas com 
superfície externa rugosa e porosa foram obtidas quando se utilizou 20 mL de diclorometano 
como fase interna e adicionou-se isopropanol à fase externa da emulsão. Essas microesferas foram 
capazes de controlar a liberação do piroxicam durante 50 h. Os resultados obtidos demonstraram 
que é possível obter micropartículas com características específicas pela otimização das condições 
empregadas no processo de encapsulação. 
In this study, poly(hydroxybutyrate) microparticles containing piroxicam were prepared by 
the oil-in-water emulsion-solvent evaporation method. The effects of some process conditions 
on drug content were determined using a 23 factorial design. The piroxicam loading efficiency 
varied from 5.5 to 89.8 %. Hollow and irregular microparticles with drug crystals on their surfa-
ces were obtained when 5 mL of chloroform was used as the internal phase. In the release study, 
all of the piroxicam was released to the dissolution medium (phosphate buffer pH 7.4) after 8 h. 
Small spherical microspheres with a rough and porous polymeric matrix were obtained when 20 
mL of dichloromethane was used as the internal phase and isopropanol was added to the external 
aqueous phase. These microspheres controlled the piroxicam release for approximately 50 h. The 
results demonstrated that it is possible to obtain microparticles with specific characteristics by the 
optimization of the process conditions.
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Introduction
The development of new drug delivery systems is 
considered an important approach to obtain a desired 
pharmacological effect in an efficient manner, which is 
preferable to altering the chemical nature of the drug. 
This approach can be applied to prolong drug release 
and improve therapeutic efficacy, safety and patient 
compliance. Several polymers have been used to obtain 
drug delivery systems; however, aliphatic polyesters are by 
far the most preferable ones, due to their biodegradation 
and biocompatibility characteristics. In particular, the 
polyhydroxyalkanoates (PHAs) have received special 
attention as promising biomaterials for the preparation of 
microparticulate drug carriers.1-2 The first and most reported 
PHA is poly(3-hydroxybutyrate) [PHB], the degradation 
of which leads to the formation of 3-hydroxybutiric acid, 
which is one of the three endogenous ketones produced 
by a process known as ketogenesis. Also, low molecular 
weight PHBs, complexed to other macromolecules, are 
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able to pervade aqueous as well as hydrophobic regions 
of the cells and, thus, they can be found in cytoplasm 
and intracellular fluids, as well as in membranes and 
lipoproteins. Furthermore, linear or cyclic oligomers and/
or derivatives of 3-hydroxyacids can be administrated 
orally in order to increase the blood ketone levels as a 
nutritional or dietary supplement, which is useful for 
seizure control, metabolic disease control, increasing 
cardiac efficiency, and the treatment of diabetes and other 
disorders. Thus, it is assumed that PHB, along with its 
oligomers and monomers, is not toxic to cells, and can 
even provide some therapeutic or nutritional benefits.3
Several techniques can be used to prepare polymeric 
microparticles. The choice of the technique depends 
on the characteristics of the polymer, the drug and the 
intended use. The emulsion-solvent evaporation method 
is the one most frequently used to prepare microspheres. 
In this process, the drug and the polymer are dissolved in 
an organic phase, which is emulsified in an aqueous phase 
containing a stabilizing agent, under stirring. The organic 
solvent diffuses into the aqueous phase and it evaporates at 
the water/air interface. The microparticles are then washed, 
collected and dried.4-6 The characteristics of microparticles 
obtained through this technique are affected by process 
parameters such as solvent, temperature, volume ratio 
of disperse-continuous phase, type and concentration of 
the emulsifier, drug/polymer ratio and stirring rate.7 The 
solvent removal kinetics can affect the physicochemical 
properties of the microparticles, in particular the surface 
morphology and porosity, which in turn affects the rate of 
drug release. 
In this study, the processing conditions that affect the 
characteristics of the PHB microparticles were determined 
in order to obtain microparticles with high piroxicam 
(PXC) loading efficiencies and the potential to control 
drug release. Piroxicam is extensively used in the treatment 
of osteoarthritis and rheumatoid arthritis in elderly 
patients, but as with other nonsteroidal anti-inflammatory 
drugs (NSAIDs), PXC is well known for its gastrotoxic 
and duodenotoxic effects when used orally.8 Thus, the 
incorporation of this drug in PHB microparticles offers 
a means not only to control the drug release, but also to 
minimize or eliminate the local side effects. A reduction in 
the oral side effects of NSAIDs can be also accomplished 
through the injection of the drug at the site of inflammation 
(intraarticular, for example).9 However, the short synovial 
half-life of NSAIDs would require frequent injections to 
maintain therapeutic levels.10 Therefore, biodegradable 
and biocompatible PHB microparticles show potential 






 = 312,800 g mol-1 and 
polydispersity degree of 1.23, determined by gel permeation 
chromatography) was kindly supplied by PHB Industrial 
S.A. (Serrana, São Paulo, Brazil). Piroxicam was purchased 
from Deg Imp. Produtos Químicos (São Paulo, Brazil) 
and poly(vinyl alcohol) (M
n
 = 92,000 g mol-1, according 
to information supplied by the manufacturer) from Vetec 
(Rio de Janeiro, Brazil). Isopropanol, dichloromethane 
and chloroform were acquired from Nuclear, Brazil; 
Tedia Company, USA and Vetec, Brazil, respectively. All 
chemicals were used without further purification.
Preparation of microparticles
PHB/PXC microparticles were prepared by the oil-
in-water emulsion-solvent evaporation technique. The 
polymer (500 mg) and the drug (200 mg) were dissolved 
in an organic solvent (internal phase) and then emulsified 
in 200 mL of an aqueous phase containing 0.15 % (m/v) 
of poly(vinyl alcohol) [PVA] as stabilizer (external phase). 
When necessary, 6% (v/v) of isopropanol was added to 
the aqueous phase. The resulting emulsion was stirred at 
700 rpm, at room temperature, until the evaporation of 
the organic solvent. The microparticles were washed with 
distilled water, dried and stored under vacuum at room 
temperature. In order to determine the effect of some 
process conditions on the efficiency of drug loading, the 
experiments were performed using a 23 factorial design. 
The independent variables analyzed were: the type of 
the organic solvent of the internal phase, the volume of 
the organic solvent and the addition of isopropanol to the 
aqueous external phase. Table 1 shows the independent 
variables and their levels investigated in the preparation 
of the microspheres. The data were evaluated by analysis 
of variance (ANOVA).
Determination of drug content and loading efficiency 
(LE%)
To determine the drug content, 10 mg of microparticles 
were accurately weighed and dissolved in 10 mL 
of chloroform. The solution was diluted by a factor 
of 30 and the absorption band was determined by 
UV-Vis spectrophotometry (Perkin Elmer lambda 11/Bio 
spectrophotometer) at 327 nm. The drug concentration was 
calculated from the calibration curve. The microsphere 
drug content was then estimated and expressed as mg % 
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(mg of drug per 100 mg of microparticles). The loading 
efficiency was obtained using equation 1.
(1)
Scanning electron microscopy (SEM)
To observe the internal structure of microparticles two 
different methods were used: i) frozen particles were cut with 
a blade, and ii) the particles were embedded in a glycerol 
polyglycidyl ether resin (PELCO® Eponate 12) and sectioned 
in a Leica ultramicrotome at –70 °C, using a diamond knife. 
The microtomed samples were carbon and gold coated by 
sputtering in a Bal-Tec MD 020 instrument (Balzers). The 
morphology of the particles was examined in a JSM-6340F 
field emission scanning electron microscope (JEOL Ltd.), 
operating at an accelerating voltage of 3 kV. The arithmetic 
mean diameter was determined of at least 300 particles 
measured on micrographs obtained by SEM.
Thermal analysis
DSC curves were obtained using a Shimadzu DSC-50 
differential scanning calorimeter by heating from 25 to 
220  °C at 10 °C min-1 in a nitrogen atmosphere (50 mL min-1). 
Pore size distribution 
The pore size distributions of the samples were 
determined from nitrogen adsorption/desorption isotherms 
obtained at the temperature of liquid nitrogen in an automated 
physisorption instrument (Autosorb-1-C, Quantachrome 
Instruments). Prior to the analysis, the samples were 
outgassed under vacuum at 473 K for 3 h. Specific surface 
areas were calculated according to the Brunauer-Emmett-
Teller (BET) method, and the pore size distributions were 
obtained according to the Barret-Joyner-Hallenda (BJH) 
method from the adsorption data. 
X-ray powder diffraction analysis
X-ray patterns were obtained using a Philips X’Pert 
X-ray diffractometer. The incident radiation was Cu K
(  =1.5406 Å) and the data were collected at 2  from 5 to 35°.
Molecular weight determination
PHB molecular weight was determined by gel 
permeation chromatography (GPC) using a high-
performance liquid chromatograph (Shimadzu 10 AD). 
The analysis was carried out using a Progel  TSK G4000 
HXL column (30 cm  7.8 mm ID; Supelco). The GPC 
system was eluted with chloroform at a flow rate of 
0.8 mL min-1 at 35 °C. Polystyrene was used as the 
molecular weight standard and the molecular weight of the 
samples was calculated based on the standard curve. 
In vitro drug release
In vitro drug release studies were carried out in 
phosphate buffer solution (PBS) pH 7.4 at 37  0.5 °C 
under constant stirring (100 rpm). Microparticles 
(n = 3) containing 3 mg of drug were placed into 200 mL
of PBS and samples were withdrawn at regular time 
intervals. The samples were immediately returned to the 
dissolution vessels after analysis. The PXC concentration 
was measured by UV-Vis spectrophotometry, at 360 nm. 
At the end of the assay, the microparticles were washed 
with distilled water, centrifuged, dried under vacuum and 
the pore size distribution and the molecular weight were 
determined as previous described.
Results
Drug content and loading efficiency 
The loading efficiency and piroxicam content of the 
microparticles are presented in Table 2, where the batch 
Table 1. Independent variables and their levels investigated in the preparation of the PHB/PXC microparticles
Batch Internal phase External aqueous phase

































( ) low level; (+) high level.
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number corresponds to the conditions indicated in Table 1. 
The results of the analysis of variance (Table 3) indicated 





;  = 0.05). 
The factorial design allowed the definition of the 
process conditions which lead to higher efficiencies for 
the loading of PXC into PHB microparticles. From the 
data shown in Table 2, the conditions used to obtain the 
microparticles of batches 2 and 7, denoted by M2 and M7, 
respectively, were selected. In spite of the higher loading 
efficiency values, the microparticles prepared using the 
conditions indicated for batches 4, 6 and 8 resulted in 
large aggregates (visualized by SEM) and, therefore, were 
excluded from further analysis.
Characterization of selected microparticles
Morphological characteristics of microparticles
Figure 1 shows SEM micrographs of the microparticles 
obtained using conditions of M2 and M7. The PHB/PXC 
microparticles (M7) had a spherical shape with an average 
diameter of 31.1  9.2 m and rough surface morphology. 
The inner part of these particles (Figure 1B) showed a 
predominance of the polymeric matrix in contrast with 
the microparticles obtained using the conditions of M2, 
which had hollow and irregular shaped particles with a 
large average size of 487  89 m. From an analysis of 
the microparticle surfaces using a higher magnification, the 
PXC crystalline form at the surface of the M2 microparticles 
(Figure 1E) can be identified. 
Thermal analysis and X-ray powder diffraction analysis
The diffractogram of PXC maintained in aqueous 
medium for 24 h (Figure 2A) shows peaks at 2  of 12.0° 
and 26.5° corresponding to those published in the literature 
for the monohydrate form.12 After the microencapsulation 
of the drug in the polymeric matrix, peaks corresponding 
to PHB at 2  of 13.5° and 16.9° and peaks of PXC were 
observed in the X-ray pattern of microparticles prepared 
through the conditions of M2 and M7 (Figures 2C and 2D), 
indicating that both components of the microparticle are in 
a crystalline form. Figure 3 shows the DSC curves for PHB, 
piroxicam and polymer/drug microparticles obtained using 
the conditions of M2 and M7. The PHB shows two different 
melting temperatures at 166 °C and 176 °C ( H
f
 = 88 J g-1), 
Table 2. Loading efficiency and content of piroxicam in PHB 
microparticles
Batch Loading efficiency (%) Drug content (mg %)
1 10.6  1.8 3.2  0.5
2 89.8  4.3 25.8  1.2
3 10.0  1.8  2.7  0.5
4 53.4  10.5 15.4  3.1
5 5.5  3.3 1.6  0.9
6 61.4  1.0 19.9  0.2
7 57.7  2.4 16.6  0.7
8 71.0  2.5 21.4  0.5
Table 3. Summary of analysis of variance results obtained using loading 
efficiency as dependent variable
Sum of squares Mean square F
A 251.22 251.22 12.61*
B 9235.21 9235.21 463.44*
C 152.52 152.52 7.65*
Interaction AB 742.56 742.56 37.26*
Interaction AC 2470.09 2470.09 123.95*
Interaction BC 1572.12 1572.12 78.89*
Interaction ABC 10.24 10.24 0.514
Error 159.42 19.93
Total 14593.39
A (type of organic solvent: dichloromethane or chloroform); B (volume 
of organic solvent: 5 mL or 20 mL); C (addition of isopropanol to the 
aqueous external phase: yes or no). F
tab
 (DF = 1;8) = 5.32 (  = 0.05). 
*significance for  = 0.05.
Figure 1. Scanning electron micrographs of PHB/PXC microparticles 
obtained through the procedure denoted as M7: (A) complete microparticle 
(B) inner part incorporated in a glycerol polyglycidyl ether resin, and 
(C) surface with higher magnification. Microparticles obtained using the 
conditions of M2: (D) fractured microparticle, and (E) surface. 
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and PXC at 204 °C ( H
f
 = 101 J g-1). However, when 
PXC was maintained in aqueous medium for 24 h a peak 
at 122 °C, corresponding to dehydratation, was observed, 
indicating the presence of PXC in the monohydrate form, 
in agreement with the X-ray diffraction analysis and data 
from different polymorphic forms of piroxicam described in 
the literature.12 This peak can be observed in the DSC curve 
of the microparticles prepared using M2 conditions. One 
interesting point that can be evaluated from the DSC curves 
for the microparticles prepared using the two conditions is the 
enthalpy of fusion value ( H
f
 = 91 J g-1) which corresponds 
to the sum of the enthalpy of fusion values for the undiluted 
components, considering the percentage in the microparticle 
composition. In the DSC curves of the microparticles, only 
one melting peak, at 168 °C, can be observed. This suggests 
that PHB and PXC are melting at the same temperature. 
Figure 2. X-ray powder diffraction patterns for: (A) piroxicam (maintained in aqueous medium for 24 h); (B) PHB; (C) microparticles obtained under M2 
conditions; (D) microparticles obtained under M7 conditions.
Figure 3. DSC curves of: (A) PHB; (B) piroxicam; (C) piroxicam (maintained in aqueous medium for 24 h); microparticles obtained using: (D) M2 
conditions; (E) M7 conditions.
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In vitro drug release
The release profiles of PXC from the PHB microparticles 
are shown in Figure 4. After 8 h and 50 h, the total amount 
of the encapsulated drug was released from the M2 and M7 
microparticles, respectively. 
Figure 5 shows the pore size distribution curves obtained 
through both procedures M2 and M7, before and after drug 
release. The pores are smaller than those of the rough texture 
observed in Figure 1. The pore size is related to the kinetics 
of the evaporation process of the organic solvent in the 
internal phase. The fast extraction of the dichloromethane 
occurred when isopropanol was added to the external phase 
(M7), originating the pores in the polymeric matrix. Also, 
the fast rate of PHB crystallization may contribute to the 
formation of a rough and porous polymeric matrix.11-13
After the release of the drug, the morphology of the 
microparticles had the same characteristics (visualized by 
SEM; micrographs not shown), the molecular weight of 
PHB remained unchanged and pores sizes between 40 and 
100 Å appear, as shown in Figure 5 (B and D), suggesting 
that the drug release occurred mainly through the desorption 
of the PXC from the microparticle surfaces (in the case 
of M2) and its diffusion through the matrix pores formed 
during the preparation of the particles and also the pores 
formed due to the drug solubilization in the dissolution 
medium (in the case of M7). 
Discussion
The oil-in-water emulsion solvent evaporation technique 
was used, in this study, to prepare PHB microparticles 
containing piroxicam as the drug model. It is well known that 
the modification of the processing conditions can affect the 
characteristics of microparticles prepared by this technique. 
The factorial design employed in this study showed that the 
type and the volume of the organic solvent of the internal 
phase and the addition of isopropanol to the aqueous external 
phase influence the PXC loading into PHB microparticles. 
These processing conditions must be controlled to obtain 
microparticles with high efficiencies of drug loading. 
The value of least significant difference obtained through 
application of the Tukey test was 17.74. When this value 
was used to compare the LE% values given in Table 2, it 
was found that the increase in the organic solvent volume 
from 5 mL to 20 mL led to a significant decrease in the 
PXC loading efficiency, except when dichloromethane was 
used as the internal phase and isopropanol was added to the 
external aqueous phase (batch 7). In this case, the addition 
of isopropanol enhances the solubility of dichloromethane in 
the aqueous phase, promoting its extraction and allowing the 
solidification of the microspheres.14 The faster elimination of 
Figure 4. Release profiles of PXC from microparticles obtained under: 
( ) M2 and ( ) M7 conditions, in phosphate buffer pH 7.4.
Figure 5. Pore diameter distribution curves, based on the BJH method: (A) M2 microparticles; (B) M2 microparticles after 8 h in phosphate buffer 
pH 7.4; (C) microparticles M7; (D) microparticles after 50 h in phosphate buffer pH 7.4.
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the organic solvent, therefore, contributed to the acceleration 
of the formation of the particles and, in turn, allowed the 
entrapment of the piroxicam in the microspheres. 
The processing conditions also influenced the size and 
morphological characteristics of the microparticles, as can 
bee seen in Figure 1. The differences in the mean size of the 
microparticles obtained using the two selected conditions 
(M2 and M7) may be associated with the PHB concentration 
in the organic phase. When using a small volume of organic 
solvent as the internal phase (M2), the polymer/drug solution 
becomes more viscous and, consequently, more resistant to 
fragmentation into small droplets which, in turn, leads to the 
generation of a coarser emulsion and, subsequently, to the 
formation of larger microspheres.15
DSC and X-ray powder diffraction analysis were used, 
in this study, to evaluate changes in the polymorphic forms 
of PXC during the microencapsulation process. Piroxicam 
shows polymorphism, occurring in three main forms: 
(needle),  (cubic) and one monohydrate form.12,16 Solvent 
polarity and crystallization kinetics are critical parameters 
for the crystallization of PXC in each polymorphic 
form.12,17 The results obtained showed the presence of 
PXC in the monohydrate form in both microparticles (M2 
and M7). The conversion to this form occurred due to the 
contact of the drug with the aqueous medium during the 
microencapsulation process.
A variety of factors can affect drug release from 
polymeric microparticles and some of these factors, such 
as microparticle size and drug distribution within the 
polymeric matrix, are related to the processing conditions 
used to prepare the microparticles. Generally, the smaller 
the mean particle diameter, the shorter the diffusion path 
for drug releases, and consequently, the faster the release 
rate.18 However, in this study, the largest microparticles 
(M2) released the PXC more rapidly, due to the presence 
of drug crystals on the microparticle surfaces and to the 
hollow structure of these particles. The surface localization 
of the drug explains the rapid initial drug release and 
short duration of release from the microparticles. The 
microspheres obtained using the M7 conditions were found 
to somewhat control the PXC release, which is associated 
with the dense matrix in the inner microparticle and to the 
location of the drug, preferentially, inside of the particles, 
which, in turn, is a result of the faster extraction of the 
organic solvent from the internal phase of the emulsion 
due to the addition of isopropanol. A fast rate of solvent 
removal can contribute to a heterogeneous distribution of 
drug within the internal phase as it hardens.15
The release of a drug from polymeric microparticles 
occurs through different mechanisms: desorption of the 
drug from the surface of the particles; diffusion of the drug 
through the pores of the polymeric matrix; erosion of the 
polymeric matrix; polymer degradation or a combination 
of different processes.5,19 As PHB is very slowly degraded, 
the release profile of a drug from a PHB matrix is 
generally dependent on drug diffusion rather than on 
polymer degradation.20 The results for the PHB molecular 
weight, pore size distributions and the morphology of the 
microparticles after the release assay indicated that the 
release of PXC from PHB microparticles occurs mainly 
through the two mechanisms: desorption of the drug from 
the surface of the particles and diffusion of the drug through 
the pores of the polymeric matrix. 
Conclusions
The results demonstrated that the process conditions 
used to prepare PHB/PXC microparticles influence its 
morphological characteristics, loading efficiency and drug 
release, indicating that it is possible to obtain microparticles 
with specific characteristics through the optimization of 
the process parameters. Using the M2 conditions it was 
possible to obtain microparticles with high efficiencies 
of PXC loading, but the presence of drug crystals on the 
surface leads to almost immediate release. On the other 
hand, the microparticles obtained using the M7 conditions 
had the desired size and morphological characteristics for 
intraarticular or intramuscular administration, indicating 
that these microparticles can be considered as a promising 
system to control drug release. 
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